Regulating angiogenesis: A new therapeutic strategy
Regulating angiogenesis: A new therapeutic strategy
复制标题
DOI：
10.1002/j.1552-4604.1998.tb04384.x
复制
发表时间：
1998-10-01
影响因子：
2.9
通讯作者：
Gibaldi, M
中科院分区：
文献类型：
--
作者：
Gibaldi, M
血管生成是内皮细胞和平滑肌细胞增殖形成新血管。在青春期后，血管生成基本上是沉默的，可能会被癌细胞重新点燃。新生血管生成在肿瘤生长和转移中起主要作用。限制甚至逆转肿瘤生长的抗血管生成疗法正在研究中，并显示出前景。富马青霉素的衍生物TNP 470是第一个用于人类的血管生成抑制剂。令人惊讶的是，一些有效的抑制剂来源于肿瘤本身。研究人员现在认识到，刺激血管生成可能在心血管疾病的治疗中占有一席之地。通过血管生成重建缺血组织的血流可能为缺血性心脏病患者提供生物学“旁路”。这同样适用于周围血管疾病的治疗。
Angiogenesis is the proliferation of endothelial and smooth muscle cells to form new blood vessels. Largely muted after adolescence, angiogenesis may be reignited by cancerous cells. Neoangiogenesis plays a primary role in tumor growth and metastases. Antiangiogenic therapy to limit and even reverse the growth of tumors are under investigation and showing promise. A derivative of fumagillin, TNP 470, is the first angiogenesis inhibitor to be given to humans. Surprisingly, several potent inhibitors are derived from tumors themselves. Researchers now recognize that stimulation of angiogenesis may have a place in the treatment of cardiovascular disease. Reestablishing blood flow to ischemic tissue through angiogenesis may provide a biologic "bypass" for patients with ischemic heart disease. The same applies to the treatment of peripheral vascular disease.